| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
A 75925 targets the HIV-1 protease, a key enzyme in the viral replication cycle. By inhibiting the protease, it prevents the cleavage of viral polyproteins into functional proteins, thereby blocking the maturation of new infectious viral particles. This makes it a valuable tool for studying HIV-1 replication and resistance mechanisms.
|
|---|---|
| ln Vitro |
In vitro, A 75925 is a potent inhibitor of HIV-1 protease. Its activity is measured in biochemical assays using recombinant HIV-1 protease and a fluorogenic peptide substrate. The compound's ability to inhibit the cleavage of the substrate is used to calculate its IC50, demonstrating its potency as a protease inhibitor.
|
| ln Vivo |
In vivo, A 75925 inhibits HIV-1 replication in cell-based assays. Its ability to block viral replication in infected cell cultures is a key measure of its efficacy. It is used in research to study the effects of protease inhibition on HIV-1 life cycle and to select for resistant viral strains.
|
| Enzyme Assay |
The in vitro enzyme assay for A 75925 involves incubating the compound with recombinant HIV-1 protease and a fluorogenic substrate that mimics the viral cleavage site. The enzyme cleaves the substrate, producing a fluorescent signal. The decrease in fluorescence in the presence of the inhibitor is measured to determine the IC50, which quantifies the compound's potency.
|
| Cell Assay |
Cellular in vitro experiments use HIV-1-infected human cell lines, such as MT-4 or CEM cells. The cells are treated with A 75925, and viral replication is measured by quantifying the production of viral proteins (e.g., p24 antigen) or by assessing the cytopathic effect. The half-maximal effective concentration (EC50) is calculated to determine the compound's antiviral activity.
|
| Animal Protocol |
In vivo animal experiments for A 75925 are not detailed in the search results. For HIV research, animal models are limited, but the compound could be studied in humanized mouse models or other surrogate systems to evaluate its antiviral efficacy and pharmacokinetics, though such data are not provided.
|
| References |
| Molecular Formula |
C44H54N4O8
|
|---|---|
| Molecular Weight |
766.94
|
| Exact Mass |
766.394
|
| CAS # |
129467-48-7
|
| PubChem CID |
72290
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.205g/cm3
|
| Boiling Point |
995.9ºC at 760 mmHg
|
| Flash Point |
556.1ºC
|
| Vapour Pressure |
0mmHg at 25°C
|
| Index of Refraction |
1.585
|
| LogP |
7.154
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
21
|
| Heavy Atom Count |
56
|
| Complexity |
1090
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
C1C=CC(COC(N[C@H](C(N[C@H]([C@H]([C@@H]([C@@H](NC([C@@H](NC(OCC2C=CC=CC=2)=O)C(C)C)=O)CC2C=CC=CC=2)O)O)CC2C=CC=CC=2)=O)C(C)C)=O)=CC=1
|
| InChi Key |
TZRRVSCDIPHXHN-RRUVMKMCSA-N
|
| InChi Code |
InChI=1S/C44H54N4O8/c1-29(2)37(47-43(53)55-27-33-21-13-7-14-22-33)41(51)45-35(25-31-17-9-5-10-18-31)39(49)40(50)36(26-32-19-11-6-12-20-32)46-42(52)38(30(3)4)48-44(54)56-28-34-23-15-8-16-24-34/h5-24,29-30,35-40,49-50H,25-28H2,1-4H3,(H,45,51)(H,46,52)(H,47,53)(H,48,54)/t35-,36-,37-,38-,39+,40+/m0/s1
|
| Chemical Name |
benzyl N-[(2S)-1-[[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]-1,6-diphenylhexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate
|
| Synonyms |
A 75925 A-75925 A75925
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3039 mL | 6.5194 mL | 13.0388 mL | |
| 5 mM | 0.2608 mL | 1.3039 mL | 2.6078 mL | |
| 10 mM | 0.1304 mL | 0.6519 mL | 1.3039 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
